Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8N5S9

UPID:
KKCC1_HUMAN

ALTERNATIVE NAMES:
CaM-kinase IV kinase; Calcium/calmodulin-dependent protein kinase kinase alpha

ALTERNATIVE UPACC:
Q8N5S9; Q9BQH3

BACKGROUND:
The enzyme Calcium/calmodulin-dependent protein kinase kinase 1, also known as CaM-kinase IV kinase, plays a significant role in cellular signaling, triggered by calcium. It is involved in phosphorylating several key proteins such as CAMK1 and AKT1/PKB, thereby regulating apoptosis and promoting cell survival.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Calcium/calmodulin-dependent protein kinase kinase 1 offers promising avenues for developing novel therapeutic approaches, especially in diseases where cell survival mechanisms are disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.